tolvaptan has been researched along with Diabetic Nephropathies in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujioka, H; Imamura, T; Kakeshita, K; Kinugawa, K; Koike, T; Yamazaki, H | 1 |
| Hoshiyama, A; Kamata, Y; Masaki, T; Shichiri, M; Takada, T; Toki, T | 1 |
| Amaha, M; Matsumura, D; Nakamura, T; Nomura, M; Ono, Y; Sato, E; Ueda, Y; Yamagishi, H | 1 |
| Imamura, T | 1 |
| Nakamura, T; Node, K; Sato, E; Tanaka, A | 1 |
5 other study(ies) available for tolvaptan and Diabetic Nephropathies
| Article | Year |
|---|---|
Expression of aquaporin-2 in the collecting duct and responses to tolvaptan.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Biomarkers, Pharmacological; Diabetic Nephropathies; Heart Failure; Humans; Immunohistochemistry; Kidney Tubules, Collecting; Male; Middle Aged; Tolvaptan; Urinary Tract Infections | 2021 |
Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diabetic Nephropathies; Drug Resistance; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Nephrotic Syndrome; Renal Insufficiency; Severity of Illness Index; Sodium Potassium Chloride Symporter Inhibitors; Time Factors; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance | 2018 |
Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzazepines; Diabetic Nephropathies; Female; Heart Failure; Humans; Kidney; Male; Middle Aged; Nephrotic Syndrome; Retrospective Studies; Tolvaptan | 2014 |
Aquaporin-2-guided tolvaptan therapy in patients with congestive heart failure accompanied by chronic kidney disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzazepines; Diabetic Nephropathies; Female; Humans; Male; Nephrotic Syndrome; Tolvaptan | 2014 |
Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzazepines; Biomarkers; Diabetic Nephropathies; Female; Heart Failure; Humans; Nephrotic Syndrome; Tolvaptan; Treatment Outcome | 2016 |